Transverse myelitis halts AstraZeneca vaccine trial against Covid19

Share on facebook
Share on twitter
Share on whatsapp
Share on telegram
Share on email

The reason AstraZeneca has announced that it is discontinuing trials with its promising coronavirus vaccine is the development of transverse myelitis in one of the study participants, reports The New York Times.

The vaccine against Covid 19 developed by the University of Oxford is one of the most promising and advanced. In a statement released Tuesday night, they explained that they had to review their research after one of the volunteers experienced a harmful side effect.

The disease that has been detected in one of the 30,000 AstraZeneca volunteers in phase 3 is an inflammation of the spinal cord. This neurological disorder may damage the insulating material that covers the nerve cell fibers (myelin).

This disease interrupts the messages that the nerves of the spinal cord send to the rest of the body and suffering from transverse myelitis can cause pain, muscle weakness, paralysis, sensory problems or dysfunction of the bladder and intestine, according to the Mayo Clinic of Minnesota.

Treatment to overcome it includes medications along with rehabilitation therapy. Most sufferers make at least partial recovery, although people with severe seizures sometimes have significant disabilities.

Latests News